指南与共识前列腺癌

基于人群的结构化前列腺特异性抗原筛查在前列腺癌中的应用:欧洲泌尿外科学会2019年立场

Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
指南 / 共识 · Eur Urol · 2019-05-12

该立场文件指出,对55-69岁无症状男性使用前列腺特异性抗原(PSA)筛查可降低癌症特异性死亡率并促使分期下移,但非选择性使用可导致过度诊断和过度治疗。欧洲泌尿外科学会(EAU)支持通过个性化风险分层方法进行适当检测,建议45岁时基线PSA联合家族史、种族等因素制定筛查间隔,并考虑多参数磁共振成像和风险计算器分诊活检需求。

要点

  • 55-69岁无症状男性PSA筛查与癌症特异性死亡率降低相关,约需筛查100人预防1例前列腺癌死亡。
  • EAU支持通过个性化风险分层方法进行适当PSA检测,以减少过度诊断和过度治疗。
  • 建议45岁时基线PSA联合家族史、种族等因素制定筛查间隔,并考虑多参数磁共振成像分诊活检。

核心结论

  • EAU支持通过PSA检测鼓励适当的前列腺癌检测,同时减少过度诊断和过度治疗,这些目标可通过个性化风险分层方法实现。

研究设计与样本

  • 欧洲泌尿外科学会(EAU)2019年立场文件,基于人群筛查证据综述。

主要发现

  • 55-69岁无症状男性PSA筛查与疾病分期下移和癌症特异性死亡率降低相关,测试后20年约需筛查100人预防1例前列腺癌死亡。
  • 非选择性使用PSA检测和根治性治疗可导致过度诊断和过度治疗。
  • 45岁时基线PSA水平可用于个体化筛查间隔。
  • 应考虑多参数磁共振成像以及基于家族史、种族、直肠指检和前列腺体积的风险计算器来分诊活检需求,从而降低过度诊断风险。

关键数值与推荐

  • 筛查对象为55-69岁无症状男性。
  • 测试后20年约需筛查100人预防1例前列腺癌死亡。
  • 建议45岁时进行基线PSA血液检测以个体化筛查间隔。
  • 应考虑多参数磁共振成像和基于家族史、种族、直肠指检和前列腺体积的风险计算器分诊活检需求。
  • 鼓励对低危和部分中危前列腺癌且充分知情的患者进行主动监测,以降低过度治疗风险而不影响肿瘤学结局。

临床怎么用

  • 应考虑在人群层面实施基于PSA的筛查。
  • 有前列腺癌风险的男性应进行基线PSA血液检测(例如45岁时)。
  • 该检测水平联合家族史、种族和其他因素可用于确定后续随访。
  • 磁共振成像扫描和新生物标志物应用于确定哪些男性需要活检以及癌症应如何治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe. Screening in asymptomatic men (aged 55-69yr) using prostate-specific antigen (PSA) is associated with a migration toward lower staged disease and a reduction in cancer-specific mortality. By 20yr after testing, around 100 men need to be screened to prevent one PCa death. While this ratio is smaller than for breast and colon cancer, the long natural history of PCa means many men die from other causes. As such, the nonselective use of PSA testing and radical treatments can lead to overdiagnosis and overtreatment. The European Association of Urology (EAU) supports measures to encourage appropriate PCa detection through PSA testing, while reducing overdiagnosis and overtreatment. These goals may be achieved using personalized risk-stratified approaches. For diagnosis, the greatest benefit from early detection is likely to come in men assessed using baseline PSA levels at the age of 45yr to individualize screening intervals. Multiparametric magnetic resonance imaging as well as risk calculators based on family history, ethnicity, digital rectal examination, and prostate volume should be considered to triage the need for biopsy, thus reducing the risk of overdiagnosis. For treatment, the EAU advocates balancing patient's life expectancy and cancer's mortality risk when deciding an approach. Active surveillance is encouraged in well-informed patients with low-risk and some intermediate-risk cancers, as it decreases the risks of overtreatment without compromising oncological outcomes. Conversely, the EAU advocates radical treatment in suitable men with more aggressive PCa. Multimodal treatment should be considered in locally advanced or high-grade cancers. PATIENT SUMMARY: Implementation of prostate-specific antigen (PSA)-based screening should be considered at a population level. Men at risk of prostate cancer should have a baseline PSA blood test (eg, at 45yr). The level of this test, combined with family history, ethnicity, and other factors, can be used to determine subsequent follow-up. Magnetic resonance imaging scans and novel biomarkers should be used to determine which men need biopsy and how any cancers should be treated.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gandaglia G, Albers P, Abrahamsson PA, et al. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. Eur Urol. 2019. PMID: 31092338. doi:10.1016/j.eururo.2019.04.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。